Armistice Capital (CHRN) reports 187,151 shares, 4.99% ownership
Rhea-AI Filing Summary
Ekso Bionics Holdings, Inc. reporting persons Armistice Capital, LLC and Steven Boyd amend a Schedule 13G/A to disclose beneficial ownership of 187,151 shares of Common Stock, representing 4.99% of the class as stated in Item 4. The filing identifies Armistice Capital as investment manager of the Master Fund and Mr. Boyd as its managing member. The ownership figures are presented in the filing with an as of reference to 03/31/2026 on the cover.
Positive
- None.
Negative
- None.
Insights
Filing is a routine Schedule 13G/A amendment reporting sub-5% passive ownership.
Armistice Capital and Steven Boyd jointly file an amendment under Rule 13d-1(k) showing 187,151 shares and 4.99% ownership. The statement describes manager-client relationships and includes the Master Fund's disclaimer regarding voting/dispositive inability.
Effect is informational; subsequent filings may update holdings. The filing preserves required disclosures about shared voting and dispositive powers.
Holder reported a non-control stake just below 5% threshold.
The report lists shared voting and dispositive power of 187,151 shares, equal to 4.99%. That percentage places the position under the 5% reporting threshold for certain Schedule 13D triggers and is consistent with a passive reporting posture.
Market impact is likely limited; changes above 5.00% would materially alter disclosure obligations.
Key Figures
Key Terms
Schedule 13G/A regulatory
Investment Management Agreement financial
Beneficial ownership regulatory
FAQ
What does the Schedule 13G/A filed by Armistice Capital mean for CHRN?
Does the filing indicate control of Ekso Bionics (CHRN)?
What date and identifier are associated with this filing for CHRN?
Does the Master Fund claim beneficial ownership in the filing for CHRN?
AI-generated analysis. How Rhea-AI works. Not financial advice.